Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Fifteen-year analysis of prostate biopsies in Western Australia including recent impact of multiparametric magnetic resonance imaging.

England T, Li J, Cohen RJ.

ANZ J Surg. 2019 Dec;89(12):1605-1609. doi: 10.1111/ans.15566. Epub 2019 Nov 25.

PMID:
31769189
2.

Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.

Mannaerts CK, Gayet M, Verbeek JF, Engelbrecht MRW, Savci-Heijink CD, Jager GJ, Gielens MPM, van der Linden H, Beerlage HP, de Reijke TM, Wijkstra H, Roobol MJ.

Eur Urol Oncol. 2018 Jun;1(2):109-117. doi: 10.1016/j.euo.2018.02.010. Epub 2018 May 15.

PMID:
31100233
3.

Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study.

van der Leest M, Cornel E, Israël B, Hendriks R, Padhani AR, Hoogenboom M, Zamecnik P, Bakker D, Setiasti AY, Veltman J, van den Hout H, van der Lelij H, van Oort I, Klaver S, Debruyne F, Sedelaar M, Hannink G, Rovers M, Hulsbergen-van de Kaa C, Barentsz JO.

Eur Urol. 2019 Apr;75(4):570-578. doi: 10.1016/j.eururo.2018.11.023. Epub 2018 Nov 23.

4.

Value of 3-Tesla multiparametric magnetic resonance imaging and targeted biopsy for improved risk stratification in patients considered for active surveillance.

Pessoa RR, Viana PC, Mattedi RL, Guglielmetti GB, Cordeiro MD, Coelho RF, Nahas WC, Srougi M.

BJU Int. 2017 Apr;119(4):535-542. doi: 10.1111/bju.13624. Epub 2016 Sep 3.

5.

The Efficacy of Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Risk Classification for Patients with Prostate Cancer on Active Surveillance.

Recabal P, Assel M, Sjoberg DD, Lee D, Laudone VP, Touijer K, Eastham JA, Vargas HA, Coleman J, Ehdaie B.

J Urol. 2016 Aug;196(2):374-81. doi: 10.1016/j.juro.2016.02.084. Epub 2016 Feb 23.

6.

The influence of prostate-specific antigen density on positive and negative predictive values of multiparametric magnetic resonance imaging to detect Gleason score 7-10 prostate cancer in a repeat biopsy setting.

Hansen NL, Barrett T, Koo B, Doble A, Gnanapragasam V, Warren A, Kastner C, Bratt O.

BJU Int. 2017 May;119(5):724-730. doi: 10.1111/bju.13619. Epub 2016 Sep 8.

7.

Utility of multiparametric magnetic resonance imaging suspicion levels for detecting prostate cancer.

Rais-Bahrami S, Siddiqui MM, Turkbey B, Stamatakis L, Logan J, Hoang AN, Walton-Diaz A, Vourganti S, Truong H, Kruecker J, Merino MJ, Wood BJ, Choyke PL, Pinto PA.

J Urol. 2013 Nov;190(5):1721-1727. doi: 10.1016/j.juro.2013.05.052. Epub 2013 May 29.

8.

Utility of early transperineal template-guided prostate biopsy for risk stratification in men undergoing active surveillance for prostate cancer.

Voss J, Pal R, Ahmed S, Hannah M, Jaulim A, Walton T.

BJU Int. 2018 Jun;121(6):863-870. doi: 10.1111/bju.14100. Epub 2018 Jan 17.

9.

Outcomes of Serial Multiparametric Magnetic Resonance Imaging and Subsequent Biopsy in Men with Low-risk Prostate Cancer Managed with Active Surveillance.

Hsiang W, Ghabili K, Syed JS, Holder J, Nguyen KA, Suarez-Sarmiento A, Huber S, Leapman MS, Sprenkle PC.

Eur Urol Focus. 2019 May 27. pii: S2405-4569(19)30148-8. doi: 10.1016/j.euf.2019.05.011. [Epub ahead of print]

PMID:
31147263
10.

Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.

Brown LC, Ahmed HU, Faria R, El-Shater Bosaily A, Gabe R, Kaplan RS, Parmar M, Collaco-Moraes Y, Ward K, Hindley RG, Freeman A, Kirkham A, Oldroyd R, Parker C, Bott S, Burns-Cox N, Dudderidge T, Ghei M, Henderson A, Persad R, Rosario DJ, Shergill I, Winkler M, Soares M, Spackman E, Sculpher M, Emberton M.

Health Technol Assess. 2018 Jul;22(39):1-176. doi: 10.3310/hta22390.

11.

Not All Multiparametric Magnetic Resonance Imaging-targeted Biopsies Are Equal: The Impact of the Type of Approach and Operator Expertise on the Detection of Clinically Significant Prostate Cancer.

Stabile A, Dell'Oglio P, Gandaglia G, Fossati N, Brembilla G, Cristel G, Dehò F, Scattoni V, Maga T, Losa A, Gaboardi F, Cardone G, Esposito A, De Cobelli F, Del Maschio A, Montorsi F, Briganti A.

Eur Urol Oncol. 2018 Jun;1(2):120-128. doi: 10.1016/j.euo.2018.02.002. Epub 2018 May 15.

PMID:
31100235
12.

Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.

Alberts AR, Roobol MJ, Verbeek JFM, Schoots IG, Chiu PK, Osses DF, Tijsterman JD, Beerlage HP, Mannaerts CK, Schimmöller L, Albers P, Arsov C.

Eur Urol. 2019 Feb;75(2):310-318. doi: 10.1016/j.eururo.2018.07.031. Epub 2018 Aug 3.

PMID:
30082150
13.

The diagnostic accuracy of multiparametric magnetic resonance imaging before biopsy in the detection of prostate cancer.

Otti VC, Miller C, Powell RJ, Thomas RM, McGrath JS.

BJU Int. 2019 Jan;123(1):82-90. doi: 10.1111/bju.14420. Epub 2018 Jul 26.

14.

Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature.

Fütterer JJ, Briganti A, De Visschere P, Emberton M, Giannarini G, Kirkham A, Taneja SS, Thoeny H, Villeirs G, Villers A.

Eur Urol. 2015 Dec;68(6):1045-53. doi: 10.1016/j.eururo.2015.01.013. Epub 2015 Feb 2. Review.

PMID:
25656808
15.

Confirmatory biopsy of men under active surveillance: extended versus saturation versus multiparametric magnetic resonance imaging/transrectal ultrasound fusion prostate biopsy.

Pepe P, Cimino S, Garufi A, Priolo G, Russo GI, Giardina R, Reale G, Pennisi M, Morgia G.

Scand J Urol. 2017 Aug;51(4):260-263. doi: 10.1080/21681805.2017.1313310. Epub 2017 May 17.

PMID:
28513296
16.

Comparison of Prostate Biopsy with or without Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Detection: An Observational Cohort Study.

Bryant RJ, Hobbs CP, Eyre KS, Davies LC, Sullivan ME, Shields W, Sooriakumaran P, Verrill CL, Gleeson FV, MacPherson RE, Hamdy FC, Brewster SF.

J Urol. 2019 Mar;201(3):510-519. doi: 10.1016/j.juro.2018.09.049.

PMID:
30266332
17.

Detection of Gleason 6 prostate cancer in patients with clinically significant prostate cancer on multiparametric magnetic resonance imaging.

Chaloupka M, Bischoff R, Pfitzinger P, Lellig E, Ledderose S, Buchner A, Schlenker B, Stief C, Clevert DA, Apfelbeck M.

Clin Hemorheol Microcirc. 2019;73(1):105-111. doi: 10.3233/CH-199223.

PMID:
31561351
18.

Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image-fusion guided transperineal prostate biopsy in patients with a previous negative biopsy.

Hansen NL, Kesch C, Barrett T, Koo B, Radtke JP, Bonekamp D, Schlemmer HP, Warren AY, Wieczorek K, Hohenfellner M, Kastner C, Hadaschik B.

BJU Int. 2017 Nov;120(5):631-638. doi: 10.1111/bju.13711. Epub 2016 Dec 21.

19.

Multicentre evaluation of magnetic resonance imaging supported transperineal prostate biopsy in biopsy-naïve men with suspicion of prostate cancer.

Hansen NL, Barrett T, Kesch C, Pepdjonovic L, Bonekamp D, O'Sullivan R, Distler F, Warren A, Samel C, Hadaschik B, Grummet J, Kastner C.

BJU Int. 2018 Jul;122(1):40-49. doi: 10.1111/bju.14049. Epub 2017 Nov 15.

20.

A multiparametric magnetic resonance imaging-based risk model to determine the risk of significant prostate cancer prior to biopsy.

van Leeuwen PJ, Hayen A, Thompson JE, Moses D, Shnier R, Böhm M, Abuodha M, Haynes AM, Ting F, Barentsz J, Roobol M, Vass J, Rasiah K, Delprado W, Stricker PD.

BJU Int. 2017 Dec;120(6):774-781. doi: 10.1111/bju.13814. Epub 2017 Mar 31.

Supplemental Content

Support Center